Download PDF
Thromb Haemost 2018; 118(05): 830-841
DOI: 10.1055/s-0038-1637745
Coagulation and Fibrinolysis
Schattauer GmbH Stuttgart

Contribution of Factor VIII A2 Domain Residues 400–409 to a Factor X-Interactive Site in the Factor Xase Complex

Masahiro Takeyama
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
,
Keiji Nogami
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
,
Kana Sasai
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
,
Shoko Furukawa
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
,
Midori Shima
1   Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
› Author Affiliations
Further Information

Publication History

06 May 2017

04 February 2018

Publication Date:
03 April 2018 (online)

Also available at
    Permissions and Reprints

Abstract

The link between factor (F)VIII and FX is essential for optimum activity of the tenase complex. The interactive site(s) in FVIII for FX remains to be completely clarified, however. We investigated the FVIII A2 domain-FX association that was speculated from inhibitory mechanism(s) by an anti-A2 autoantibody. SDS-PAGE demonstrated that the purified inhibitor IgG recognizing residues 373–562 blocked FXa cleavage at Arg372 in FVIII, and surface-plasmon resonance (SPR)-based assays showed that intact A2 subunit directly bound to FX (K d; 63 nM). The FVIII structure model indicated possible FX-binding site(s) in residues 400–429 in A2. One peptide corresponding to residues 400–409 competitively inhibited both the A2–FX binding and FVIIIa/FIXa-dependent FXa generation. Covalent cross-linking was observed between this peptide and FX following reaction with EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) using SDS-PAGE. K408 and S409 were not evident in N-terminal sequence analysis of the cross-linked product, suggesting that two residues participated in cross-link formation. SPR-based assays using recombinant FVIII mutants with one or both residues substituted to alanine demonstrated that K408A and K408A/S409A had approximately fourfold high K d values of wild-type (WT-)FVIII. FXa cleavages at Arg372 in both mutants were significantly delayed, suggesting a contribution of K408 for FXa cleavage at Arg372. Furthermore, FXa generation assays with these mutants demonstrated that the K m values were 1.4- to 1.7-fold greater, and overall catalytic efficiency (k cat/K m) was 0.49- to 0.89-fold lower than with WT-FVIII, suggesting a significant contribution of K408 for FVIII–FX interaction in tenase assembly. We concluded that the K408 in the A2 domain provided an interactive-site for FX.

Keywords

factor VIII - A2 domain - factor X - binding site - tenase complex

Financial Support

This work was partly supported by a Grant-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to M.T. (no. 26461592) and to K.N. (no. 15K09663).


Authors' Contributions

M.T. designed the research, performed experiments, interpreted the data and wrote the paper; K.N. designed the research, interpreted the data, wrote the paper and edited the manuscript; K.S. performed mutagenesis, expression and purification of FVIII mutants; S.F. performed SPR assay; M.S. supervised the manuscript.


Note

An account of this work was presented at the 56th (San Francisco, California, United States, 2014) and at the 58th (San Diego, California, United States, 2016) annual meetings of the American Society of Hematology.


 

  • References

  • 1 Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76 (01) 1-16
    PubMedGoogle Scholar
  • 2 Vehar GA, Keyt B, Eaton D. , et al. Structure of human factor VIII. Nature 1984; 312 (5992): 337-342
    CrossrefPubMedGoogle Scholar
  • 3 Wood WI, Capon DJ, Simonsen CC. , et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312 (5992): 330-337
    CrossrefPubMedGoogle Scholar
  • 4 Fay PJ, Anderson MT, Chavin SI, Marder VJ. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 1986; 871 (03) 268-278
    CrossrefPubMedGoogle Scholar
  • 5 Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263 (21) 10451-10455
    PubMedGoogle Scholar
  • 6 Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 1988; 263 (11) 5230-5234
    PubMedGoogle Scholar
  • 7 Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269 (15) 11601-11605
    PubMedGoogle Scholar
  • 8 Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25 (02) 505-512
    CrossrefPubMedGoogle Scholar
  • 9 Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 10 Nogami K, Lapan KA, Zhou Q, Wakabayashi H, Fay PJ. Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain. J Biol Chem 2004; 279 (16) 15763-15771
    CrossrefPubMedGoogle Scholar
  • 11 Nogami K, Freas J, Manithody C, Wakabayashi H, Rezaie AR, Fay PJ. Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain. J Biol Chem 2004; 279 (32) 33104-33113
    CrossrefPubMedGoogle Scholar
  • 12 Takeyama M, Wakabayashi H, Fay PJ. Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase. Biochemistry 2012; 51 (03) 820-828
    CrossrefPubMedGoogle Scholar
  • 13 Oh J, Lim Y, Jang MJ, Huh JY, Shima M, Oh D. Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A. Blood Res 2013; 48 (01) 58-62
    CrossrefPubMedGoogle Scholar
  • 14 Shima M, Scandella D, Yoshioka A. , et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69 (03) 240-246
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92 (01) 136-142
    CrossrefPubMedGoogle Scholar
  • 16 Takeyama M, Nogami K, Matsumoto T. , et al. Possible assessment of coagulation function and haemostasis therapy using comprehensive coagulation assays in a patient with acquired haemophilia A. Haemophilia 2017; 23 (01) e46-e50
    CrossrefPubMedGoogle Scholar
  • 17 Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20 (04) 833-840
    CrossrefPubMedGoogle Scholar
  • 18 Nogami K, Wakabayashi H, Schmidt K, Fay PJ. Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa. J Biol Chem 2003; 278 (03) 1634-1641
    CrossrefPubMedGoogle Scholar
  • 19 Lollar P, Fay PJ, Fass DN. Factor VIII and factor VIIIa. Methods Enzymol 1993; 222: 128-143
    PubMedGoogle Scholar
  • 20 Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999; 274 (42) 29826-29830
    CrossrefPubMedGoogle Scholar
  • 21 Ngo JC, Huang M, Roth DA, Furie BC, Furie B. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008; 16 (04) 597-606
    CrossrefPubMedGoogle Scholar
  • 22 Carraway KL, Koshland Jr DE. [56] Carbodiimide modification of proteins. Methods Enzymol 1972; 25: 616-623
    PubMedGoogle Scholar
  • 23 Takeyama M, Wakabayashi H, Fay PJ. Contribution of factor VIII light-chain residues 2007-2016 to an activated protein C-interactive site. Thromb Haemost 2013; 109 (02) 187-198
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Shen BW, Spiegel PC, Chang CH. , et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008; 111 (03) 1240-1247
    CrossrefPubMedGoogle Scholar
  • 25 Autin L, Miteva MA, Lee WH, Mertens K, Radtke KP, Villoutreix BO. Molecular models of the procoagulant factor VIIIa-factor IXa complex. J Thromb Haemost 2005; 3 (09) 2044-2056
    CrossrefPubMedGoogle Scholar
  • 26 Soeda T, Nogami K, Nishiya K. , et al. The factor VIIIa C2 domain (residues 2228-2240) interacts with the factor IXa Gla domain in the factor Xase complex. J Biol Chem 2009; 284 (06) 3379-3388
    CrossrefPubMedGoogle Scholar
  • 27 Nogami K, Shima M, Hosokawa K. , et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999; 274 (43) 31000-31007
    CrossrefPubMedGoogle Scholar
  • 28 Bloem E, Meems H, van den Biggelaar M, Mertens K, Meijer AB. A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX. J Biol Chem 2013; 288 (36) 26105-26111
    CrossrefPubMedGoogle Scholar
  • 29 Lapan KA, Fay PJ. Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 1997; 272 (04) 2082-2088
    CrossrefPubMedGoogle Scholar
  • 30 Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 1998; 273 (30) 19049-19054
    CrossrefPubMedGoogle Scholar
  • 31 Lenting PJ, Donath MJ, van Mourik JA, Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 1994; 269 (10) 7150-7155
    PubMedGoogle Scholar
  • 32 Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89 (07) 2413-2421
    CrossrefPubMedGoogle Scholar